Results 311 to 320 of about 322,587 (327)
Some of the next articles are maybe not open access.
Investigational Angiogenesis Inhibitors
2010Targeting angiogenesis is an evolving field of cancer research. Tumor angiogenesis is considered as an important step in the progression and metastasis of prostate cancer. Several pathways that converge toward promotion of growth, proliferation, and survival of prostate cancer cells have been targeted, including modulation of proangiogenic factors such
Jeanny B. Aragon-Ching, William Dahut
openaire +1 more source
Identification of novel angiogenesis inhibitors
Bioorganic & Medicinal Chemistry Letters, 2005Vascular endothelial growth factor (VEGF) is a key stimulant of angiogenesis, which is the process of generating new capillary blood vessels. Inhibition of the vascular endothelial growth factor receptor (VEGFR) kinase is known to result in blockage of angiogenesis.
Jayalakshmi, Sridhar +5 more
openaire +2 more sources
Angiogenesis and angiogenesis inhibitors in cancer.
Forum (Genoa, Italy), 1999Angiogenesis, the development of a new blood supply, is an essential process of tumour growth and metastasis. Over the past few years, this has led to the consideration of the tumour vasculature as an optimal target for anti-cancer strategies. The process of angiogenesis consists of a series of interactive events: quiescent endothelial cells are ...
R, Giavazzi, G, Taraboletti
openaire +1 more source
Angiogenesis inhibitors in lung cancer
Current Oncology Reports, 2002Lung cancer is a major public health problem and the leading cause of cancer-related death worldwide. Its survival rates have changed little over the past 20 years. The best clinical benefit (ie, survival rates) with combination cytotoxic therapies in non-small-cell lung cancer (NSCLC) may have been reached.
Edward S, Kim, Roy S, Herbst
openaire +2 more sources
[Tumor angiogenesis and tumor angiogenesis inhibitors].
Gan to kagaku ryoho. Cancer & chemotherapy, 2001It is important to survey the molecular targets which are involved in tumor angiogenesis for the development of antiangiogenic agents as one of the cancer therapy. This article is meant to review the recent molecular targets of tumor angiogenesis and the molecular mechanism of antiangiogenic agents in human clinical trials.
M, Ono, M, Kuwano
openaire +1 more source
Angiogenesis Inhibitors as Cancer Therapy
Hospital Practice, 1999Angiogenesis inhibitors target a tumor's need to obtain nourishment from the host. In general, they are predicted to be chiefly cytostatic--that is, they stabilize tumors and perhaps prevent metastasis rather than being curative. Nevertheless, it remains conceivable that these agents may trigger tumor cell death.
openaire +2 more sources